| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |